45.33
0.69 (1.55%)
| Previous Close | 44.64 |
| Open | 44.73 |
| Volume | 719,307 |
| Avg. Volume (3M) | 1,478,087 |
| Market Cap | 5,431,818,752 |
| Price / Sales | 13.14 |
| Price / Book | 19.14 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Scholar Rock Holding Corporatio | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.20 |
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | 45.33 | - | 6,839 | 310,012 |
| BRUDNICK RICHARD | 45.33 | - | 6,839 | 310,012 |
| BUROW KRISTINA | 45.33 | - | 6,839 | 310,012 |
| FLIER JEFFREY S. | 45.33 | - | 6,839 | 310,012 |
| GILMAN MICHAEL | 45.33 | - | 6,839 | 310,012 |
| PENG KATIE | 45.33 | - | 6,839 | 310,012 |
| REED JOSHUA | 45.33 | - | 6,839 | 310,012 |
| Aggregate Net Quantity | 47,873 | |||
| Aggregate Net Value ($) | 2,170,083 | |||
| Aggregate Avg. Buy ($) | 45.33 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | 04 Jun 2026 | Acquired (+) | 6,839 | 45.33 | 310,012 |
| PENG KATIE | Director | 04 Jun 2026 | Acquired (+) | 6,839 | 45.33 | 310,012 |
| GILMAN MICHAEL | Director | 04 Jun 2026 | Acquired (+) | 6,839 | 45.33 | 310,012 |
| BUROW KRISTINA | Director | 04 Jun 2026 | Acquired (+) | 6,839 | 45.33 | 310,012 |
| BRUDNICK RICHARD | Director | 04 Jun 2026 | Acquired (+) | 6,839 | 45.33 | 310,012 |
| REED JOSHUA | Director | 04 Jun 2026 | Acquired (+) | 6,839 | 45.33 | 310,012 |
| FLIER JEFFREY S. | Director | 04 Jun 2026 | Acquired (+) | 6,839 | 45.33 | 310,012 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |